Focused On-demand Library for Osteopetrosis-associated transmembrane protein 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q86WC4

UPID:

OSTM1_HUMAN

Alternative names:

Chloride channel 7 beta subunit

Alternative UPACC:

Q86WC4; E1P5E3; Q5R391; Q6PCA7; Q7RTW6; Q8NC29; Q8TC82; Q9Y2S9

Background:

Osteopetrosis-associated transmembrane protein 1, also known as Chloride channel 7 beta subunit, plays a crucial role in osteoclast and melanocyte maturation and function. This protein is pivotal for the proper development and activity of cells responsible for bone resorption and pigmentation.

Therapeutic significance:

Mutations in this protein lead to Osteopetrosis, autosomal recessive 5, a rare genetic disorder characterized by dense bone and systemic complications. Understanding the role of Osteopetrosis-associated transmembrane protein 1 could open doors to potential therapeutic strategies for treating severe bone sclerosis, growth failure, and visual impairments associated with this condition.